Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype

• Abstracts
• Supplementary data

Hidradenitis suppurativa among patients with new-onset inflammatory bowel disease - Results from the IBD Prognosis Study Get access

• Abstracts
• Supplementary data

Graphical Abstract Get access

Graphical abstract

Triple Biologic Therapy for Refractory Crohn’s Disease Get access

• Abstract

Biglycan deficiency alleviates intestinal fibrosis through BMP-7-mediated Smad1/5/8 signaling Get access

• Abstract
• Supplementary data

Histology in IBD: A Redundant Tool or a Valuable Prognostic Marker? Get access

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn’s Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY) Get access

• Abstracts
• Supplementary data

Graphical abstract Get access

Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis Get access

• Abstract
• Supplementary data

Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU Get access

• Abstracts

Graphical abstract Get access

Graphical Abstract Get access

Association of Bile Acid Diarrhea with Symptoms and Disease Activity in Crohn’s Disease: Post-Hoc Clinical Trial Analysis of Serum 7a-hydroxy-4cholestern-3-one, C4, in Patients with Active Crohn’s Disease Get access

• Abstracts
• Supplementary data

The mediating role of psychological inflexibility on internalised stigma and patient outcomes in a sample of adults with inflammatory bowel disease

• Abstract
• Supplementary data

Corticosteroid-free clinical and endoscopic outcomes in the overall populat...

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicentre retrospective cohort study

• Abstracts
• Supplementary data

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

• Abstracts
• Supplementary data

Graphical abstract

Graphical abstract Get access